Abstract:Background and Objectives Neurodegeneration and astrocytic activation are pathologic hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP). We investigated sNfL and sGFAP as tools for stratifying patients with progressive MS based on progression and disease activity status. Methods We leveraged our Comprehensive Longitudinal Investigation of MS at the Brigham and Women9s Hospital (CLIMB) natural history study, which includes clinical, MRI data and serum samples collected over more than 20 years. We included patients with MS with a confirmed Expanded Disability Status Scale (EDSS) score ≥3 that corresponds with our classifier for patients at high risk of underlying progressive pathology. We analyzed sNfL and sGFAP within 6 months from the confirmed EDSS score ≥3 corresponding with our baseline visit. Patients who further developed 6-month confirmed disability progression (6mCDP) were classified as progressors. We further stratified our patients into active/nonactive based on new brain/spinal cord lesions or relapses in the 2 years before baseline or during follow-up. Statistical analysis on log-transformed sGFAP/sNfL assessed the baseline association with demographic, clinical, and MRI features and associations with future disability. Results We included 257 patients with MS who had an average EDSS score of 4.0 and a median follow-up after baseline of 7.6 years. sNfL was higher in patients with disease activity in the 2 years before baseline (adjusted β = 1.21; 95% CI 1.04–1.42; p = 0.016), during the first 2 years of follow-up (adjusted β = 1.17; 95% CI = 1.01–1.36; p = 0.042). sGFAP was not increased in the presence of disease activity. Higher sGFAP levels, but not sNfL levels, were associated with higher risk of 6mCDP (adjusted hazard ratio [HR] = 1.71; 95% CI = 1.19–2.45; p = 0.004). The association was stronger in patients with low sNfL (adjusted HR = 2.44; 95% CI 1.32–4.52; p = 0.005) and patients who were nonactive in the 2 years prior or after the sample. Discussion Higher levels of sGFAP correlated with subsequent progression, particularly in nonactive patients, whereas sNfL reflected acute disease activity in patients with MS at high risk of underlying progressive pathology. Thus, sGFAP and sNfL levels may be used to stratify patients with progressive MS for clinical research studies and clinical trials and may inform clinical care.

Longitudinal correlation of cerebrospinal fluid GFAP and the progression of cognition decline in different clinical subtypes of Parkinson's disease

Clinical significance of serum glial fibrillary acidic protein level in middle-aged and elderly patients with Parkinson's disease

Plasma GFAP in Parkinson’s Disease with Cognitive Impairment and Its Potential to Predict Conversion to Dementia

Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson's disease

Plasma GFAP As a Prognostic Biomarker of Motor Subtype in Early Parkinson’s Disease

Plasma Glial Fibrillary Acidic Protein As a Biomarker of Disease Progression in Parkinson’s Disease: a Prospective Cohort Study

Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson's disease

Association of Cortical Gyrification With Imaging and Serum Biomarkers in Patients With Parkinson Disease

Serum glial cell line-derived neurotrophic factor: a potential biomarker for white matter alteration in Parkinson's disease with mild cognitive impairment

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

The association of CSF biomarkers and cognitive decline with choroid plexus volume in early Parkinson's disease

Progressive Brain Atrophy in Parkinson's Disease Patients Who Convert to Mild Cognitive Impairment.

The Association of the Glymphatic Function with Parkinson's Disease Symptoms: Neuroimaging Evidence from Longitudinal and Cross-Sectional Studies

Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson's disease

Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease

Estimated glomerular filtration rate is a biomarker of cognitive impairment in Parkinson's disease

Association of Cortical and Subcortical Microstructure with Clinical Progression and Fluid Biomarkers in Patients With Parkinson Disease

Estimated Glomerular Filtration Rate is a Biomarker of Cognitive Impairment in Parkinson’s Disease

CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.

Plasma glial fibrillary acidic protein in Alzheimer’s disease and other neurodegenerative disorders: relationship to diagnosis, biomarkers, neuropathology and longitudinal progression

Baseline concentration of misfolded α-synuclein aggregates in cerebrospinal fluid predicts risk of cognitive decline in Parkinson's disease.